CAMBRIDGE, Mass.--()--The STT Radio Exclusive Interview will be held on Tuesday, January 8, at 8:00pm EST, and will discuss the Company’s recent announcements.
It can be heard live at the IHub Auditorium at http://www.investorshub.advfn.com/boards/auditorium.aspx, or directly from our STT Live Page at http://stocktraderstalk.com/edvp-ceo-interview-edward-w-withrow-iii-8pmest-182013. An archived recorded version of the interview can be found and heard on the homepage of STT Radio at http://www.stocktraderstalk.com immediately following the live interview.
About Stock Traders Talk:
Stock Traders Talk Radio is a centralized portal for investors. We specialize in LIVE radio interviews and believe that when a CEO has the ability to demonstrate their passion, and talking points about their company it serves as the ultimate delivery platform. Press Releases have value; however, they lack the ability for a CEO to connect with shareholders and potential shareholders.
Stock Traders Talk Radio is a comprehensive uncensored approach to analyzing OTC stocks, with additional focuses on penny stocks in play, world markets, SEC and Regulations and interesting ROI opportunities.
Listeners can interact with the show via our main chat room at http://www.stocktraderstalk.com.
ABOUT ENDEAVOR POWER CORPORATION
Endeavor Power Corp is a fully reporting Nevada corporation traded on the OTCQB under the symbol “EDVP.QB”. The Company is headquartered in Cambridge, MA. Parallax Diagnostics, Ltd (“Parallax”) is a bio-medical company focused on infectious diseases, which owns a line of proprietary, FDA approved, Point of Care diagnostic tests on a single proprietary platform. Parallax is developing a novel, handheld diagnostic testing system that is simple, rapid and elegant, offering the potential to transform the diagnostic landscape by transitioning critical tests from the centralized lab directly to the hands of the physician or clinicians. Our focus is on tests that detect and/or monitor infectious diseases. The Company’s tests combine innovative technologies that provide accessible, practical and rapid point of care in vitro diagnostics are based on the Company’s Target System, its FDA Approved Platform that centered on the Target System VT1000, an FDA Approved bench top fluorescence immunoassay spectrum analyzer and its innovative flow through Target System test cartridges. Parallax Diagnostics, Inc. is a Nevada corporation and a wholly owned subsidiary of Endeavor Power Corp. For more information: www.endeavorpowercorp.com or visit Endeavor Power Corp. on Facebook, Twitter, and YouTube.
Safe Harbor Statement:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.